for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Foamix Pharmaceuticals Ltd

FOMX.OQ

Latest Trade

3.62USD

Change

0.05(+1.40%)

Volume

135,551

Today's Range

3.52

 - 

3.69

52 Week Range

1.97

 - 

6.20

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
3.57
Open
3.60
Volume
135,551
3M AVG Volume
14.86
Today's High
3.69
Today's Low
3.52
52 Week High
6.20
52 Week Low
1.97
Shares Out (MIL)
61.00
Market Cap (MIL)
217.78
Forward P/E
-2.39
Dividend (Yield %)
--

Next Event

Foamix Pharmaceuticals Ltd at Cantor Fitzgerald Global Healthcare Conference

Latest Developments

More

Foamix Pharmaceuticals Ltd Says May From Time To Time Offer And Sell Ordinary Shares Having Aggregate Offering Price Of Up To $30 Million

Foamix Submits New Drug Application To FDA For Fmx103 For The Treatment Of Moderate-To-Severe Papulopustular Rosacea

Foamix Submits New Drug Application To U.S. FDA For FMX103 For The Treatment Of Moderate-To-Severe Papulopustular Rosacea

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Foamix Pharmaceuticals Ltd

Foamix Pharmaceuticals Ltd. is a clinical-stage pharmaceutical company. The Company is engaged in the development and commercialization of foam-based formulations, using its technology, which includes its foam platforms. It is focused on developing and commercializing its minocycline foam for the treatment of acne, rosacea and other skin conditions. Its product candidates include FMX101, FMX102, FMX103 and FDX104. Its lead product candidate, FMX101, is a topical foam formulation of the antibiotic minocycline for the treatment of moderate-to-severe acne. FMX102 is a formulation of its minocycline foam being developed for the treatment of impetigo. FMX103 is a topical foam formulation of minocycline for the treatment of moderate-to-severe Papulopustular rosacea. FDX104 is a topical foam formulation of the antibiotic doxycycline for the treatment of severe acne-like rashes induced by chemotherapy. It has conducted one Phase II clinical trial for each of FMX101, FMX102, FMX103 and FDX104.

Industry

Biotechnology & Drugs

Contact Info

2 Holzman Street, Rehovot Science Park

+972.8.9316233

http://www.foamix.com/

Key Stats

1.83 mean rating - 6 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (USD)

2016

-0.910

2017

-1.760

2018

-1.700

2019(E)

-1.492
Price To Earnings (TTM)
--
Price To Sales (TTM)
107.12
Price To Book (MRQ)
3.22
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-119.04
Return on Equity (TTM)
-93.55

Latest News

Foamix's treatment for common skin condition meets late-stage trial goals

Foamix Pharmaceuticals Ltd said on Wednesday its experimental foam treatment for rosacea, a common skin condition that causes acne-like bumps and redness on the face, met the main goals of two late-stage clinical trials.

Foamix acne drug meets main goals in late-stage trial, shares surge

Foamix Pharmaceuticals Ltd said on Tuesday that its lead drug treating moderate-to-severe acne met the main goals of its third late-stage study, sending its shares up 57 percent in extended trading.

Foamix Pharma's acne drug meets main goals in late-stage trial

Foamix Pharmaceuticals Ltd said on Tuesday that its drug treating moderate-to-severe acne met the main goals of its third late-stage study.

BRIEF-Foamix Reports Fiscal Year 2017 Financial Results And Provides Corporate Update

* FOAMIX REPORTS FISCAL YEAR 2017 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

BRIEF-Tamarkin Medical Reports 7.3 Percent Passive Stake In Foamix Pharmaceuticals

* TAMARKIN MEDICAL INNOVATIONS LTD REPORTS 7.3 PERCENT PASSIVE STAKE IN FOAMIX PHARMACEUTICALS AS OF DECEMBER 31, 2017 - SEC FILING Source text: (http://bit.ly/2so9g8s) Further company coverage:

BRIEF-Foamix Announces Positive Results From Late Stage Acne Treatment Study

* FOAMIX ANNOUNCES POSITIVE RESULTS FROM PHASE 3 OPEN-LABEL SAFETY EXTENSION EVALUATING FMX-101 TOPICAL MINOCYCLINE FOAM FOR TREATMENT UP TO 1 YEAR Source text for Eikon: Further company coverage:

BRIEF-Foamix Names David Domzalski As A Member Of Company Board

* FOAMIX NAMES MR. DAVID DOMZALSKI AS A MEMBER OF THE BOARD OF FOAMIX PHARMACEUTICALS

BRIEF-Foamix Q3 loss per share $0.47

* Foamix reports third quarter 2017 financial results and provides business update

BRIEF-Foamix Q2 loss per share $0.44

* Foamix reports second quarter 2017 financial results and provides business update

BRIEF-Foamix says expects to report top-line results from study FX2017-22 by mid-2018​

* Foamix announces dosing of first patient in third phase 3 acne study for minocycline foam fmx101

BRIEF-Foamix Pharmaceuticals appoints David Domzalski as CEO

* Foamix Pharmaceuticals appoints David Domzalski as chief executive officer

BRIEF-Foamix announces dosing of first patient in phase 3 rosacea clinical trials

* Foamix announces dosing of first patient in phase 3 rosacea clinical trials for FMX103 minocycline foam 1.5%

BRIEF-Foamix Pharmaceuticals reports Q1 2017 financial results

* Foamix reports first quarter 2017 financial results and provides business update

BRIEF-Foamix Pharmaceuticals announces plans for additional phase 3 trial for FMX101 in moderate to severe acne

* Foamix Pharmaceuticals announces plans for additional phase 3 trial for fmx101 in moderate to severe acne

Foamix's acne drug misses main goal in key study, shares slump

Foamix Pharmaceuticals Ltd said on Monday its experimental acne treatment failed to meet one of two main goals in a late-stage study, pushing its shares down about 42 percent.

Foamix's acne drug misses main goal in key study, shares slump

Foamix Pharmaceuticals Ltd said on Monday its experimental acne treatment failed to meet one of two main goals in a late-stage study, pushing its shares down about 42 percent.

BRIEF-Foamix reports topline results from phase 3 trials for fmx101

* Foamix reports topline results from phase 3 trials for fmx101 in patients with acne

BRIEF-Foamix Pharmaceuticals may offer its ordinary shares of up to $291.9 mln

* Says it may offer its ordinary shares of up to $291.9 million Source text:(http://bit.ly/2l8MAk1) Further company coverage:

BRIEF-Foamix reports year end 2016 financial results and provides business update

* Foamix reports year end 2016 financial results and provides business update

BRIEF-Foamix announces completion of patient enrollment in phase 3 acne trials for Minocycline Foam FMX101

* Foamix announces completion of patient enrollment in phase 3 acne trials for Minocycline Foam FMX101

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up